MarketInOut Stock Screener Log In | Sign Up
 

Cogent Biosciences Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/10/2026 15:52
Cogent Biosciences Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,078.58 mln
Float173 mln
Earnings Date11/10/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

55.82
Transformational upside

Relative Strength

22 / 100
Significantly lagging

Debt / Equity

0.46
Low leverage

ROE

-84.42
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Cogent Biosciences is a clinical-stage company working to develop targeted treatments for patients with specific genetic mutations that drive serious diseases. Its most advanced drug, bezuclastinib, is currently in Phase 3 testing and aims to treat conditions such as systemic mastocytosis and certain gastrointestinal tumors by blocking the faulty protein signals that cause them. The company also has several earlier-stage drugs in development targeting other genetic abnormalities found in cancers including bile duct cancer and solid tumors. Based in Waltham, Massachusetts, Cogent operates under a licensing agreement with Plexxikon Inc. covering the development and commercialization of its lead treatment.

Key Fundamentals

EPS-2.16
ROE-84.42
ROIC-909
ROA-55.86
EBITDA, mln-367
EV / EBITDA-15.07
EV / EBIT-14.87

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price55.82
Short Ratio9.61
Short % of Float10.67

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.27% 43 / 100   
1 Month -11.81% 18 / 100   
2 Months 5.8% 76 / 100   
6 Months -5.4% 31 / 100   
1 Year 166% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us